|
Benazepril hydrochloride
Benazepril hydrochloride (Lotensin)
Benazepril hydrochloride
(beh-
NAYZ-eh-prill)
Pregnancy Category: D
Lotensin
(Rx)
Classification:
Antihypertensive, ACE inhibitor
See Also:
See also
Angiotensin-Converting Enzyme Inhibitors.
[
]
Action/Kinetics:
Both supine and standing BPs are reduced with mild-to-moderate hypertension and no compensatory tachycardia. Also an antihypertensive effect in clients with low-renin hypertension. Food does not affect the extent of absorption. Almost completely converted to the active benazeprilat, which has greater ACE inhibitor activity.
Onset: 1 hr.
Duration: 24 hr.
Peak plasma levels, benazepril: 30-60 min.
Peak plasma levels, benazeprilat: 1-2 hr if fasting and 2-4 hr if not fasting.
t
1/2, benazeprilat: 10-11 hr.
Peak reduction in BP: 2-4 hr after dosing.
Peak effect with chronic therapy: 1-2 weeks. Highly bound to plasma protein and excreted through the urine with about 20% of a dose excreted as benazeprilat.
Uses:
Alone or in combination with thiazide diuretics to treat hypertension.
Contraindications:
Hypersensitivity to benazepril or any other ACE inhibitor.
Special Concerns:
Use with caution during lactation. Safety and effectiveness have not been determined in children.
Side Effects:
CNS: Headache, dizziness, fatigue, anxiety, insomnia, drowsiness, nervousness.
GI: N&V;, constipation, abdominal pain, gastritis, melena, pancreatitis.
CV: Symptomatic hypotension, postural hypotension, syncope, angina pectoris, palpitations, peripheral edema, ECG changes.
Dermatologic: Flushing, photosensitivity, pruritus, rash, diaphoresis.
GU: Decreased libido, impotence, UTI.
Respiratory: Cough, asthma, bronchitis, dyspnea, sinusitis, bronchospasm.
Neuromuscular: Paresthesias, arthralgia, arthritis, asthenia, myalgia.
Hematologic: Occasionally, eosinophilia, leukopenia, neutropenia, decreased hemoglobin.
Miscellaneous: Angioedema, which may be associated with involvement of the tongue, glottis, or larynx; hypertonia; proteinuria; hyponatremia; infection.
Laboratory Test Alterations:
 Serum creatinine, BUN, serum potassium.
 Hemoglobin. ECG changes.
Drug Interactions:
-
Diuretics / Excessive
in BP
-
Lithium /
Serum lithium levels with
risk of lithium toxicity
-
Potassium-sparing diuretics, potassium supplements /
Risk of hyperkalemia
How Supplied:
Tablet: 5 mg, 10 mg, 20 mg, 40 mg
Dosage
?Tablets
Clients not receiving a diuretic.
Initial: 10 mg once daily;
maintenance: 20-40 mg/day given as a single dose or in two equally divided doses. Total daily doses greater than 80 mg have not been evaluated.
Clients receiving a diuretic.
Initial: 5 mg/day.
C
CR < 30 mL/min/1.73 m
2. The recommended starting dose is 5 mg/day;
maintenance: titrate dose upward until BP is controlled or to a maximum total daily dose of 40 mg. |
